RE:RE:RE:mdjbrown...I don't understand "mystery partner named as I havent dug that deep yet alleyesonme, but trying to connect the dots based on public disclosure has been interesting. We know Medipharm has an FDA approved CBD facility, but I am not sure if some of the other big name defendants also hold the same distinction.
Trying to narrow it down though.
“This was initiated in relation to MediPharm's Cannabidiol Active Pharmaceutical Ingredient (API) Drug Master File (DMF) being referenced in an Abbreviated New Drug Application (ANDA) submitted to the FDA in September 2022 by a global pharmaceutical company” https://www.newswire.ca/news-releases/medipharm-labs-makes-first-delivery-of-cannabis-clinical-trial-material-to-us-research-partner-and-provides-update-on-us-fda-status 861407414.html#:~:text=This%20was%20initiated%20in%20relation,by%20a%20global%20pharmaceutical%20company. Without knowing actual submission dates each defendant sent their ANDA application, we can only guess based on Paragraph IV Certificate dates and ANDA numbers assuming they are issued by the FDA in numerical order.
176. Pursuant to Section 505 of the FFDCA, Teva filed ANDA No. 217508 seeking approval to engage in the commercial manufacture, use, sale, offer for sale, or importation of Teva’s Proposed Product, before certain patents-in-suit expire. 177. No earlier than November 21, 2022, Teva sent written notice of a Paragraph IV Certification (“Teva’s Notice Letter”) to GW. 182. Pursuant to Section 505 of the FFDCA, Apotex filed ANDA No. 217699 seeking approval to engage in the commercial manufacture, use, sale, offer for sale, or importation of Apotex’s Proposed Product, before certain patents-in-suit expire. 183. No earlier than November 28, 2022, Apotex sent written notice of a Paragraph IV Certification (“Apotex’s Notice Letter”) to GW https://www.documentcloud.org/documents/23562739-dnj-2-23-cv-00018-1-1